The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.
Age 18-65 at the time of consent, weighing between 132 and 250 pounds
Ability and willingness to sign informed consent
Available for the study period
Willing to use contraception for the duration of the study
Women: positive urine pregnancy test at screening or day of dosing
Women who are lactating or intend to become pregnant during the study period.
Acute or chronic clinically significant hematologic, pulmonary, cardiovascular, hepatic, or renal functional abnormality as determined by medical history, physical examination or laboratory screening.
History of allergic reaction to tafenoquine or primaquine.